Physician profile
Lynn Ebaugh
NPI 1568559862
$3,628.84
in general payments reported to CMS, 2019-2025
19 companies · $15.71 in 2025
The $15.71 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $240 · 2021: $984 · 2022: $1,599 · 2023: $44.39 · 2024: $147 · 2025: $15.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $207.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $659.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $643.00 | 2019-2022 | |
| Glaxosmithkline, LLC. | $462.67 | 2021-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $432.62 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $298.65 | 2021-2025 | Crysvita |
| Fresenius USA Marketing, INC. | $186.38 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $159.52 | 2021-2022 | |
| Akebia Therapeutics INC | $158.70 | 2019-2021 | |
| Vifor Pharma, INC. | $157.74 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $118.65 | 2021-2022 | |
| Travere Therapeutics, INC. | $97.46 | 2022 | |
| Veloxis Pharmaceuticals, INC. | $95.84 | 2022 | |
| Horizon Therapeutics Plc | $50.84 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $29.41 | 2019 | |
| Baxter Healthcare | $22.07 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.13 | 2020 | |
| Calliditas Therapeutics US INC. | $13.99 | 2022 | |
| Amgen INC. | $13.83 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Ebaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.